Literature DB >> 6822725

A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection.

A Goodeve, C W Potter, A Clark, R Jennings, G C Schild, R Yetts.   

Abstract

One hundred and nineteen volunteers were divided into five groups, and each volunteer inoculated subcutaneously with an aqueous subunit B/Hong Kong/73 vaccine containing 40, 20, 10, or 5 micrograms of HA or saline alone in a 0.5 ml volume. The incidence of reactions was recorded 24 h after inoculation. One month following immunization the serum HI antibody to B/Hong Kong/73 virus was measured; each volunteer was inoculated intranasally with live, attenuated influenza B (RB77) virus; and the incidence of infection by the challenge virus was determined by HI antibody response. The results showed that the incidence of reactions to all doses of vaccine were relatively low, the severity mild, and the duration short. However, the incidence of reactions was highest for those given 40 micrograms HA and least for those given 5 micrograms HA. The serum HI antibody responses to vaccine showed a dose-response relationship. For volunteers given 40 micrograms HA, 22 (96%) showed a fourfold rise in antibody titre and all volunteers had antibody titres of greater than 40 following immunization: for volunteers given 5 micrograms HA the g.m.t. increased from 16.6 to 86.1; and for those given 10 and 20 micrograms HA the response was intermediate. Following challenge, the lowest incidence of infection was seen in volunteers given the highest dose of vaccine. However, all doses of vaccine induced some protection against challenge virus infection, and the incidence of infection was directly related to the serum antibody titre at the time of challenge. The 50% protection titre of serum HI antibody was estimated as 15 to 20.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6822725      PMCID: PMC2134195          DOI: 10.1017/s0022172400063907

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  10 in total

1.  Selective solubilization of hemagglutinin and neuraminidase from influenza viruses.

Authors:  H Bachmayer
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

2.  Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic.

Authors:  G MEIKLEJOHN; C H KEMPE; W G THALMAN; E H LENNETTE
Journal:  Am J Hyg       Date:  1952-01

Review 3.  Determinants of immunity to influenza infection in man.

Authors:  C W Potter; J S Oxford
Journal:  Br Med Bull       Date:  1979-01       Impact factor: 4.291

4.  A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines.

Authors:  G C Schild; J M Wood; R W Newman
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

5.  An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines.

Authors:  J M Wood; G C Schild; R W Newman; V Seagroatt
Journal:  J Biol Stand       Date:  1977

6.  From the National Institute of Allergy and Infectious Diseases: summary of a workshop on influenza B viruses and Reye's syndrome.

Authors:  J R LaMontagne
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

7.  Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions.

Authors:  K G Nicholson; D A Tyrrell; P Harrison; C W Potter; R Jennings; A Clark; G C Schild; J M Wood; R Yetts; V Seagroatt; A Huggins; S G Anderson
Journal:  J Biol Stand       Date:  1979-04

8.  Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines.

Authors:  C W Potter; R Jennings; K Nicholson; D A Tyrrell; K G Dickinson
Journal:  J Hyg (Lond)       Date:  1977-12

9.  Reactogenicity and immunogenicity of whole and ether-Tween-split influenza A virus vaccines in volunteers.

Authors:  R Jennings; A Clark; J S Oxford; D J Hockley; C W Potter
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

10.  Quantitation and analysis of the specificity of post-immunization antibodies to influenza B viruses using single radial haemolysis.

Authors:  J S Oxford; R Yetts; G C Schild
Journal:  J Hyg (Lond)       Date:  1982-04
  10 in total
  16 in total

1.  Age-related changes in durability and function of vaccine-elicited influenza-specific CD4(+) T-cell responses.

Authors:  Yolanda D Mahnke; Areej Saqr; Staci Hazenfeld; Rebecca C Brady; Mario Roederer; Ramu A Subbramanian
Journal:  Vaccine       Date:  2011-09-20       Impact factor: 3.641

2.  A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes.

Authors:  Laurent Coudeville; Philippe Andre; Fabrice Bailleux; Françoise Weber; Stanley Plotkin
Journal:  Hum Vaccin       Date:  2010-10-01

3.  Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies.

Authors:  W E Beyer; A M Palache; R Kerstens; N Masurel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

4.  Elderly men with moderate and intense training lifestyle present sustained higher antibody responses to influenza vaccine.

Authors:  Adriana Ladeira de Araújo; Léia Cristina Rodrigues Silva; Juliana Ruiz Fernandes; Manuella de Sousa Toledo Matias; Lucy Santos Boas; Clarisse Martins Machado; Luiz Eugênio Garcez-Leme; Gil Benard
Journal:  Age (Dordr)       Date:  2015-10-19

5.  Antibody response and persistence in volunteers following immunization with varying dosages of a trivalent surface antigen influenza virus vaccine.

Authors:  R Jennings; T L Smith; A R Mellersh; A Clark; R C Spencer; C W Potter
Journal:  J Hyg (Lond)       Date:  1985-02

6.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

7.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model.

Authors:  Laurent Coudeville; Fabrice Bailleux; Benjamin Riche; Françoise Megas; Philippe Andre; René Ecochard
Journal:  BMC Med Res Methodol       Date:  2010-03-08       Impact factor: 4.615

8.  Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus.

Authors:  Victor C Huber; Loren H Kleimeyer; Jonathan A McCullers
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

9.  Influenza epidemic among a community of elderly people in spite of vaccination.

Authors:  G Dindinaud; G Potiron; G Agius; V Ferron; C Burucoa; A Bourgoin; G Grollier; M P Peletier; E Perivier; M Castets
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

10.  A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection.

Authors:  N Masurel; J Laufer
Journal:  J Hyg (Lond)       Date:  1984-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.